17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Phase 1 Completed 60 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of 17-DMAG in treating patients with metastatic or unresectable solid tumors or lymphomas. Drugs used in chemotherapy, such as 17-DMAG, work in different ways to stop cancer cells from dividing so they stop growing or die

Timeline

Start: 2004-07
Primary completion: 2010-06
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	alvespimycin	Small molecule	—	Intravenous

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Summary

Timeline

Drugs

Indications